Oaxaca Site Management Organization S.C.
Oaxaca Site Management Organization S.C.
Humboldt 302, ruta Independencia, Colonia Centro, Oaxaca de Juárez, Oaxaca. México. CP 68000
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Flor Citlali Rojas Ramírez
Andrea Alicia Colli Domínguez
Alonso Fuentes Rivera
Alberto Ali Vicente Villavicencio
Elizabeth Vargas Mora
Sergio Garcia Mendez
Jessica Trujillo Martínez
Belem Deyanira Rendón González
Víctor C. Bohórquez López
Ana Laura Flores Barranco
Lucia Cruz Aquino
Open studies
Breast Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Lung cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) - KEYVIBE-003 - Merck Sharp & Dohme Corp.See more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Solid tumors
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) - MK-7339-002 - AstraZenecaSee more
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) - MK-3475-587 - Merck Sharp & Dohme Corp.See more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Advanced tumors
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) - MK-7339-002 - AstraZenecaSee more
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) - MK-3475-587 - Merck Sharp & Dohme Corp.See more
Diffuse sclerosis
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms - VITALISScE™ - Boehringer IngelheimSee more
Liposarcoma
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Lupus
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - POETYK SLE-2 - Bristol-Myers SquibbSee more
Ovarian cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
Prostate cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
